Literature DB >> 31687418

Neurotuberculosis: Control of Steroid-Refractory Paradoxical Inflammatory Reaction With Ruxolitinib.

Yingda L Xie1, Fanny Ita-Nagy2, Ray Y Chen1, Maura M Manion3, Irini Sereti3, Luxin Pei3, Steven M Holland4.   

Abstract

Paradoxical inflammatory reactions associated with treatment of neurotuberculosis can lead to severe morbidity and mortality and may not be controlled by steroids alone. We report the use of the Janus kinase inhibitor ruxolitinib to treat a steroid-refractory neurotuberculosis paradoxical reaction. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2019.

Entities:  

Keywords:  JAK inhibitors; neurotuberculosis; paradoxical reaction; ruxolinitib; tuberculosis

Year:  2019        PMID： 31687418      PMCID： PMC6821379          DOI： 10.1093/ofid/ofz422

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN： 2328-8957            Impact factor:   3.835


  12 in total

1.  A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.

Authors:  Denise C Hsu; Kimberly F Faldetta; Luxin Pei; Virginia Sheikh; Netanya S Utay; Gregg Roby; Adam Rupert; Anthony S Fauci; Irini Sereti
Journal:  Clin Infect Dis       Date:  2015-09-22       Impact factor: 9.079

2.  Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

Authors:  Timothy K Blackmore; Laurens Manning; William J Taylor; Robert S Wallis
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

3.  Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction.

Authors:  James S Molton; Paul J Huggan; Sophia Archuleta
Journal:  Med J Aust       Date:  2015-02-16       Impact factor: 7.738

4.  Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome.

Authors:  Yolanda D Mahnke; Jamieson H Greenwald; Rebecca DerSimonian; Gregg Roby; Lis R V Antonelli; Alan Sher; Mario Roederer; Irini Sereti
Journal:  Blood       Date:  2012-01-04       Impact factor: 22.113

5.  Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases.

Authors:  Johan F Schoeman; Graham Fieggen; Neil Seller; Marc Mendelson; Bennie Hartzenberg
Journal:  J Child Neurol       Date:  2006-04       Impact factor: 1.987

Review 6.  Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis.

Authors:  Lucy C K Bell; Ronan Breen; Robert F Miller; Mahdad Noursadeghi; Marc Lipman
Journal:  Int J Infect Dis       Date:  2015-03       Impact factor: 3.623

Review 7.  Reconsidering adjuvant immunotherapy for tuberculosis.

Authors:  Robert S Wallis
Journal:  Clin Infect Dis       Date:  2005-05-31       Impact factor: 9.079

8.  Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.

Authors:  Sameer Imtiaz; Kevin D Shield; Michael Roerecke; Andriy V Samokhvalov; Knut Lönnroth; Jürgen Rehm
Journal:  Eur Respir J       Date:  2017-07-13       Impact factor: 16.671

9.  Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system.

Authors:  L Tsenova; A Bergtold; V H Freedman; R A Young; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome.

Authors:  R Tadokera; G Meintjes; K H Skolimowska; K A Wilkinson; K Matthews; R Seldon; N N Chegou; G Maartens; M X Rangaka; K Rebe; G Walzl; R J Wilkinson
Journal:  Eur Respir J       Date:  2010-09-03       Impact factor: 16.671
View more
  1 in total

Review 1.  Paradoxical manifestations during tuberculous meningitis treatment among HIV-negative patients: a retrospective descriptive study and literature review.

Authors:  Rogelio Domínguez-Moreno; Miguel García-Grimshaw; David Medina-Julio; Carlos Cantú-Brito; Alejandra González-Duarte
Journal:  Neurol Sci       Date:  2021-10-27       Impact factor: 3.830
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.